#BEGIN_DRUGCARD DB00640

# AHFS_Codes:
92:00.00

# ATC_Codes:
C01EB10

# Absorption:
Not Available

# Biotransformation:
Intracellular adenosine is rapidly metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol.

# Brand_Mixtures:
Not Available

# Brand_Names:
Adenocard
Adenocor
Adenoscan
Adenosin
Adensoine
Boniton
Myocol
Nucleocardyl
Pallacor
Sandesin

# CAS_Registry_Number:
58-61-7

# ChEBI_ID:
16335

# Chemical_Formula:
C10H13N5O4

# Chemical_IUPAC_Name:
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2243435

# Description:
A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. [PubChem]

# Dosage_Forms:
Liquid	Intravenous
Solution	Intravenous

# Drug_Category:
Analgesics
Anti-Arrhythmia Agents
Antiarrhythmic Agents
Cardiac drugs
Vasodilator Agents

# Drug_Interactions:
Aminophylline	This xanthine decreases the effect of adenosine
Caffeine	Caffeine may diminish the therapeutic effect of adenosine. Specific management recommendations vary slightly depending on specific adenosine product used (i.e., therapeutic vs. diagnostic use of adenosine). Significantly higher adenosine doses, or alternative agents, may be required. Monitor for decreased therapeutic effects of adenosine if the patient is already receiving caffeine. Discontinue caffeine in advance (5 half-lives, or approximately 24 hours, is specifically recommended) of scheduled diagnostic use of adenosine (e.g., for radionuclide imaging studies) whenever possible.
Dipyridamole	Dipyridamole may increase the effect/toxicity of adenosine.
Dyphylline	This xanthine decreases the effect of adenosine
Oxtriphylline	This xanthine decreases the effect of adenosine
Theophylline	Theophylline may decrease the effect of adenosine.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.05

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
8230 mg/L

# Food_Interactions:
Avoid caffeine containing foods and drinks.

# GenBank_ID:
Not Available

# Generic_Name:
Adenosine

# HET_ID:
101

# Half_Life:
Less than 10 secs

# InChI_Identifier:
InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1

# InChI_Key:
InChIKey=OIRDTQYFTABQOQ-KQYNXXCUSA-N

# Indication:
Used as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT.

# KEGG_Compound_ID:
C00212

# KEGG_Drug_ID:
D00045

# LIMS_Drug_ID:
640

# Mechanism_Of_Action:
Adenosine slows conduction time through the AV node and can interrupt the reentry pathways through the AV node, resulting in the restoration of normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome. This effect may be mediated through the drug's activation of cell-surface A<sub>1</sub> and A<sub>2</sub> adenosine receptors. Adenosine also inhibits the slow inward calcium current and activation of adenylate cyclase in smooth muscle cells, thereby causing relaxation of vascular smooth muscle. By increasing blood flow in normal coronary arteries with little or no increase in stenotic arteries (with little to no increase in stenotic arteries), adenosine produces a relative difference in thallous (thallium) chloride TI 201 uptake in myocardium supplied by normal verus stenotic coronary arteries.

# Melting_Point:
235.5 Â°C

# Molecular_Weight_Avg:
267.2413

# Molecular_Weight_Mono:
267.096753929

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448049

# Pharmacology:
Adenosine is an endogenous nucleoside occurring in all cells of the body and is not chemically related to other antiarrhythmic drugs. Adenosine may exert its pharmacologic effects by activation of purine (cell surface A<sub>1</sub> and A<sub>2</sub> adenosine) receptors, as well as relax vascular smooth muscles through the reduction in calcium uptake by inhibition of slow inward calcium current and activation of adenylate cyclase in smooth muscle cells. Adenosine may reduce vascular tone by modulation of sympathetic neurotransmission. The drug also has negative chronotropic, dromotropic, and inotropic effects on the heart by slowing conduction time throught he AV node and interrupting AV nodal reentry pathways. Adenosine is a potent vasodilator in most vascular beds, but vasoconstriction is produced in renal afferent arterioles and hepatic veins. The drug produces a net mild to moderate reduction in systolic, diastolic, and mean arterial blood pressure and a reflex increase in heart rate. Adenosine is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenosine is not blocked by atropine.

# Predicted_LogP_Hydrophobicity:
-1.2

# Predicted_LogS:
-1.3

# Predicted_Water_Solubility:
1.40e+01 g/l

# Primary_Accession_No:
DB00640

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
60961

# PubChem_Substance_ID:
46508728

# RxList_Link:
http://www.rxlist.com/cgi/generic3/adenos.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00132

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
2'-Deoxyadenosine
Adenine Deoxy Nucleoside
Adenine Deoxyribonucleoside
Adenine Deoxyribose
Adenine Nucleoside
Adenine Riboside
Adenyldeoxyriboside
Deoxyadenosine
Desoxyadenosine
MEDR-640
USAF CB-10

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:31 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Adenosine

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
ADA

# Phase_1_Metabolizing_Enzyme_1_ID:
3957

# Phase_1_Metabolizing_Enzyme_1_Name:
Adenosine deaminase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Adenosine deaminase
MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPD
FLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQA
EGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAI
DLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGY
HTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIF
KSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAG
QNL

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P00813

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
ADK

# Phase_1_Metabolizing_Enzyme_2_ID:
6021

# Phase_1_Metabolizing_Enzyme_2_Name:
Adenosine kinase

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Adenosine kinase
MAAAEEEPKPKKLKVEAPQALRENILFGMGNPLLDISAVVDKDFLDKYSLKPNDQILAED
KHKELFDELVKKFKVEYHAGGSTQNSIKVAQWMIQQPHKAATFFGCIGIDKFGEILKRKA
AEAHVDAHYYEQNEQPTGTCAACITGDNRSLIANLAAANCYKKEKHLDLEKNWMLVEKAR
VCYIAGFFLTVSPESVLKVAHHASENNRIFTLNLSAPFISQFYKESLMKVMPYVDILFGN
ETEAATFAREQGFETKDIKEIAKKTQALPKMNSKRQRIVIFTQGRDDTIMATESEVTAFA
VLDQDQKEIIDTNGAGDAFVGGFLSQLVSDKPLTECIRAGHYAASIIIRRTGCTFPEKPD
FH

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P55263

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
16339914	Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9.
17321471	Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29.
17438146	Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16.
17442976	Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9.
19749080	Kreckler LM, Gizewski E, Wan TC, Auchampach JA: Adenosine suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production by murine macrophages through a protein kinase A- and exchange protein activated by cAMP-independent signaling pathway. J Pharmacol Exp Ther. 2009 Dec;331(3):1051-61. Epub 2009 Sep 11.
20136829	Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. Epub 2010 Feb 5.
20370661	Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901.
20370662	Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ADORA2A

# Drug_Target_1_GenBank_ID_Gene:
M97370

# Drug_Target_1_GenBank_ID_Protein:
177892

# Drug_Target_1_GeneCard_ID:
ADORA2A

# Drug_Target_1_Gene_Name:
ADORA2A

# Drug_Target_1_Gene_Sequence:
>1230 bp
ATGGGCTCCTCGGTGTACATCACGGTGGAGCTGGCCATTGCTGTGCTGGCCATCCTGGGC
AATGTGCTGGTGTGCTGGGCCGTGTGGCTCAACAGCAACCTGCAGAACGTCACCAACTAC
TTTGTGGTGTCACTGGCGGCGGCCGACATCGCAGTGGGTGTGCTCGCCATCCCCTTTGCC
ATCACCATCAGCACCGGGTTCTGCGCTGCCTGCCACGGCTGCCTCTTCATTGCCTGCTTC
GTCCTGGTCCTCACGCAGAGCTCCATCTTCAGTCTCCTGGCCATCGCCATTGACCGCTAC
ATTGCCATCCGCATCCCGCTCCGGTACAATGGCTTGGTGACCGGCACGAGGGCTAAGGGC
ATCATTGCCATCTGCTGGGTGCTGTCGTTTGCCATCGGCCTGACTCCCATGCTAGGTTGG
AACAACTGCGGTCAGCCAAAGGAGGGCAAGAACCACTCCCAGGGCTGCGGGGAGGGCCAA
GTGGCCTGTCTCTTTGAGGATGTGGTCCCCATGAACTACATGGTGTACTTCAACTTCTTT
GCCTGTGTGCTGGTGCCCCTGCTGCTCATGCTGGGTGTCTATTTGCGGATCTTCCTGGCG
GCGCGACGACAGCTGAAGCAGATGGAGAGCCAGCCTCTGCCGGGGGAGCGGGCACGGTCC
ACACTGCAGAAGGAGGTCCATGCTGCCAAGTCACTGGCCATCATTGTGGGGCTCTTTGCC
CTCTGCTGGCTGCCCCTACACATCATCAACTGCTTCACTTTCTTCTGCCCCGACTGCAGC
CACGCCCCTCTCTGGCTCATGTACCTGGCCATCGTCCTCTCCCACACCAATTCGGTTGTG
AATCCCTTCATCTACGCCTACCGTATCCGCGAGTTCCGCCAGACCTTCCGCAAGATCATT
CGCAGCCACGTCCTGAGGCAGCAAGAACCTTTCAAGGCAGCTGGCACCAGTGCCCGGGTC
TTGGCAGCTCATGGCAGTGACGGAGAGCAGGTCAGCCTCCGTCTCAACGGCCACCCGCCA
GGAGTGTGGGCCAACGGCAGTGCTCCCCACCCTGAGCGGAGGCCCAATGGCTATGCCCTG
GGGCTGGTGAGTGGAGGGAGTGCCCAAGAGTCCCAGGGGAACACGGGCCTCCCAGACGTG
GAGCTCCTTAGCCATGAGCTCAAGGGAGTGTGCCCAGAGCCCCCTGGCCTAGATGACCCC
CTGGCCCAGGATGGAGCAGGAGTGTCCTGA

# Drug_Target_1_General_Function:
Involved in A2A adenosine receptor activity, G-protein coupled

# Drug_Target_1_General_References:
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
1331670	Furlong TJ, Pierce KD, Selbie LA, Shine J: Molecular characterization of a human brain adenosine A2 receptor. Brain Res Mol Brain Res. 1992 Sep;15(1-2):62-6.
7775460	Kim J, Wess J, van Rhee AM, Schoneberg T, Jacobson KA: Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem. 1995 Jun 9;270(23):13987-97.
8670304	Le F, Townsend-Nicholson A, Baker E, Sutherland GR, Schofield PR: Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A. Biochem Biophys Res Commun. 1996 Jun 14;223(2):461-7.

# Drug_Target_1_HGNC_ID:
HGNC:263

# Drug_Target_1_HPRD_ID:
00043

# Drug_Target_1_ID:
1178

# Drug_Target_1_Locus:
22q11.23

# Drug_Target_1_Molecular_Weight:
44708

# Drug_Target_1_Name:
Adenosine A2a receptor

# Drug_Target_1_Number_of_Residues:
412

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Adenosine A2a receptor
MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAI
PFAITISTGFCAACHGCLFIACFVLVLTQSSIFSLLAIAIDRYIAIRIPLRYNGLVTGTR
AKGIIAICWVLSFAIGLTPMLGWNNCGQPKEGKNHSQGCGEGQVACLFEDVVPMNYMVYF
NFFACVLVPLLLMLGVYLRIFLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVG
LFALCWLPLHIINCFTFFCPDCSHAPLWLMYLAIVLSHTNSVVNPFIYAYRIREFRQTFR
KIIRSHVLRQQEPFKAAGTSARVLAAHGSDGEQVSLRLNGHPPGVWANGSAPHPERRPNG
YALGLVSGGSAQESQGNTGLPDVELLSHELKGVCPEPPGLDDPLAQDGAGVS

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase

# Drug_Target_1_SwissProt_ID:
P29274

# Drug_Target_1_SwissProt_Name:
AA2AR_HUMAN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
8.05

# Drug_Target_1_Transmembrane_Regions:
8-30
44-66
78-100
121-143
174-198
235-258
267-290

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16339914	Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9.
17321471	Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29.
17438146	Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16.
17442976	Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9.
20136829	Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. Epub 2010 Feb 5.
20370661	Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901.
20370662	Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
ADORA2B

# Drug_Target_2_GenBank_ID_Gene:
M97759

# Drug_Target_2_GenBank_ID_Protein:
178150

# Drug_Target_2_GeneCard_ID:
ADORA2B

# Drug_Target_2_Gene_Name:
ADORA2B

# Drug_Target_2_Gene_Sequence:
>999 bp
ATGCTGCTGGAGACACAGGACGCGCTGTACGTGGCGCTGGAGCTGGTCATCGCCGCGCTT
TCGGTGGCGGGCAACGTGCTGGTGTGCGCCGCGGTGGGCACGGCGAACACTCTGCAGACG
CCCACCAACTACTTCCTGGTGTCCCTGGCTGCGGCCGACGTGGCCGTGGGGCTCTTCGCC
ATCCCCTTTGCCATCACCATCAGCCTGGGCTTCTGCACTGACTTCTACGGCTGCCTCTTC
CTCGCCTGCTTCGTGCTGGTGCTCACGCAGAGCTCCATCTTCAGCCTTCTGGCCGTGGCA
GTCGACAGATACCTGGCCATCTGTGTCCCGCTCAGGTATAAAAGTTTGGTCACGGGGACC
CGAGCAAGAGGGGTCATTGCTGTCCTCTGGGTCCTTGCCTTTGGCATCGGATTGACTCCA
TTCCTGGGGTGGAACAGTAAAGACAGTGCCACCAACAACTGCACAGAACCCTGGGATGGA
ACCACGAATGAAAGCTGCTGCCTTGTGAAGTGTCTCTTTGAGAATGTGGTCCCCATGAGC
TACATGGTATATTTCAATTTCTTTGGGTGTGTTCTGCCCCCACTGCTTATAATGCTGGTG
ATCTACATTAAGATCTTCCTGGTGGCCTGCAGGCAGCTTCAGCGCACTGAGCTGATGGAC
CACTCGAGGACCACCCTCCAGCGGGAGATCCATGCAGCCAAGTCACTGGCCATGATTGTG
GGGATTTTTGCCCTGTGCTGGTTACCTGTGCATGCTGTTAACTGTGTCACTCTTTTCCAG
CCAGCTCAGGGTAAAAATAAGCCCAAGTGGGCAATGAATATGGCCATTCTTCTGTCACAT
GCCAATTCAGTTGTCAATCCCATTGTCTATGCTTACCGGAACCGAGACTTCCGCTACACT
TTTCACAAAATTATCTCCAGGTATCTTCTCTGCCAAGCAGATGTCAAGAGTGGGAATGGT
CAGGCTGGGGTACAGCCTGCTCTCGGTGTGGGCCTATGA

# Drug_Target_2_General_Function:
Involved in A2B adenosine receptor activity, G-protein coupled

# Drug_Target_2_General_References:
1325798	Pierce KD, Furlong TJ, Selbie LA, Shine J: Molecular cloning and expression of an adenosine A2b receptor from human brain. Biochem Biophys Res Commun. 1992 Aug 31;187(1):86-93.
7558011	Jacobson MA, Johnson RG, Luneau CJ, Salvatore CA: Cloning and chromosomal localization of the human A2b adenosine receptor gene (ADORA2B) and its pseudogene. Genomics. 1995 May 20;27(2):374-6.

# Drug_Target_2_HGNC_ID:
HGNC:264

# Drug_Target_2_HPRD_ID:
15971

# Drug_Target_2_ID:
268

# Drug_Target_2_Locus:
17p12-p11.2

# Drug_Target_2_Molecular_Weight:
36333

# Drug_Target_2_Name:
Adenosine A2b receptor

# Drug_Target_2_Number_of_Residues:
332

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Adenosine A2b receptor
MLLETQDALYVALELVIAALSVAGNVLVCAAVGTANTLQTPTNYFLVSLAAADVAVGLFA
IPFAITISLGFCTDFYGCLFLACFVLVLTQSSIFSLLAVAVDRYLAICVPLRYKSLVTGT
RARGVIAVLWVLAFGIGLTPFLGWNSKDSATNNCTEPWDGTTNESCCLVKCLFENVVPMS
YMVYFNFFGCVLPPLLIMLVIYIKIFLVACRQLQRTELMDHSRTTLQREIHAAKSLAMIV
GIFALCWLPVHAVNCVTLFQPAQGKNKPKWAMNMAILLSHANSVVNPIVYAYRNRDFRYT
FHKIISRYLLCQADVKSGNGQAGVQPALGVGL

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase

# Drug_Target_2_SwissProt_ID:
P29275

# Drug_Target_2_SwissProt_Name:
AA2BR_HUMAN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
8.31

# Drug_Target_2_Transmembrane_Regions:
9-31
45-67
79-101
122-144
179-203
236-259
268-291

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
16339914	Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9.
17321471	Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29.
17438146	Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16.
17442976	Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9.
20136829	Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. Epub 2010 Feb 5.
20370661	Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901.
20370662	Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
ADORA3

# Drug_Target_3_GenBank_ID_Gene:
L20463

# Drug_Target_3_GenBank_ID_Protein:
349449

# Drug_Target_3_GeneCard_ID:
ADORA3

# Drug_Target_3_Gene_Name:
ADORA3

# Drug_Target_3_Gene_Sequence:
>957 bp
ATGCCCAACAACAGCACTACTCTGTCATTGGCCAATGTTACCTACATCACCATGGAAATT
TTCATTGGACTCTGCGCCATAGTGGGCAACGTGCTGGTCATCTGCGTGGTCAAGCTGAAC
CCCAGCCTGCAGACCACCACCTTCTATTTCATTGTCTCTCTAGCCCTGGCTGACATTGCT
GTTGGGGTGCTGGTCATGCCTTTGGCCATTGTTGTCAGCCTGGGCATCACAATCCACTTC
TACAGCTGCCTTTTTATGACTTGCCTACTGCTTATCTTTACCCACGCCTCCATCATGTCC
TTGCTGGCCATCGCTGTGGACCGATACTTGCGGGTCAAGCTTACCGTCAGATACAAGAGG
GTCACCACTCACAGAAGAATATGGCTGGCCCTGGGCCTTTGCTGGCTGGTGTCATTCCTG
GTGGGATTGACCCCCATGTTTGGCTGGAACATGAAACTGACCTCAGAGTACCACAGAAAT
GTCACCTTCCTTTCATGCCAATTTGTTTCCGTCATGAGAATGGACTACATGGTATACTTC
AGCTTCCTCACCTGGATTTTCATCCCCCTGGTTGTCATGTGCGCCATCTATCTTGACATC
TTTTACATCATTCGGAACAAACTCAGTCTGAACTTATCTAACTCCAAAGAGACAGGTGCA
TTTTATGGACGGGAGTTCAAGACGGCTAAGTCCTTGTTTCTGGTTCTTTTCTTGTTTGCT
CTGTCATGGCTGCCTTTATCTATCATCAACTGCATCATCTACTTTAATGGTGAGGTACCA
CAGCTTGTGCTGTACATGGGCATCCTGCTGTCCCATGCCAACTCCATGATGAACCCTATC
GTCTATGCCTATAAAATAAAGAAGTTCAAGGAAACCTACCTTTTGATCCTCAAAGCCTGT
GTGGTCTGCCATCCCTCTGATTCTTTGGACACAAGCATTGAGAAGAATTCTGAGTAG

# Drug_Target_3_General_Function:
Involved in A3 adenosine receptor activity, G-protein coupled

# Drug_Target_3_General_References:
11214319	Murphy WJ, Eizirik E, Johnson WE, Zhang YP, Ryder OA, O'Brien SJ: Molecular phylogenetics and the origins of placental mammals. Nature. 2001 Feb 1;409(6820):614-8.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.
8234299	Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG: Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10365-9.
8399349	Sajjadi FG, Firestein GS: cDNA cloning and sequence analysis of the human A3 adenosine receptor. Biochim Biophys Acta. 1993 Oct 7;1179(1):105-7.

# Drug_Target_3_HGNC_ID:
HGNC:268

# Drug_Target_3_HPRD_ID:
08984

# Drug_Target_3_ID:
390

# Drug_Target_3_Locus:
1p13.2

# Drug_Target_3_Molecular_Weight:
36185

# Drug_Target_3_Name:
Adenosine A3 receptor

# Drug_Target_3_Number_of_Residues:
318

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_3_Protein_Sequence:
>Adenosine A3 receptor
MPNNSTALSLANVTYITMEIFIGLCAIVGNVLVICVVKLNPSLQTTTFYFIVSLALADIA
VGVLVMPLAIVVSLGITIHFYSCLFMTCLLLIFTHASIMSLLAIAVDRYLRVKLTVRYKR
VTTHRRIWLALGLCWLVSFLVGLTPMFGWNMKLTSEYHRNVTFLSCQFVSVMRMDYMVYF
SFLTWIFIPLVVMCAIYLDIFYIIRNKLSLNLSNSKETGAFYGREFKTAKSLFLVLFLFA
LSWLPLSIINCIIYFNGEVPQLVLYMGILLSHANSMMNPIVYAYKIKKFKETYLLILKAC
VVCHPSDSLDTSIEKNSE

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Possible role in reproduction

# Drug_Target_3_SwissProt_ID:
P33765

# Drug_Target_3_SwissProt_Name:
AA3R_HUMAN

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
9.04

# Drug_Target_3_Transmembrane_Regions:
15-37
49-72
85-106
127-148
178-198
232-255
262-284

# Drug_Target_4_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17321471	Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29.
17438146	Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16.
17442976	Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9.
20136829	Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. Epub 2010 Feb 5.
20370661	Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901.
20370662	Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
ADORA1

# Drug_Target_4_GenBank_ID_Gene:
S45235

# Drug_Target_4_GenBank_ID_Protein:
256155

# Drug_Target_4_GeneCard_ID:
ADORA1

# Drug_Target_4_Gene_Name:
ADORA1

# Drug_Target_4_Gene_Sequence:
>981 bp
ATGCCGCCCTCCATCTCAGCTTTCCAGGCCGCCTACATCGGCATCGAGGTGCTCATCGCC
CTGGTCTCTGTGCCCGGGAACGTGCTGGTGATCTGGGCGGTGAAGGTGAACCAGGCGCTG
CGGGATGCCACCTTCTGCTTCATCGTGTCGCTGGCGGTGGCTGATGTGGCCGTGGGTGCC
CTGGTCATCCCCCTCGCCATCCTCATCAACATTGGGCCACAGACCTACTTCCACACCTGC
CTCATGGTTGCCTGTCCGGTCCTCATCCTCACCCAGAGCTCCATCCTGGCCCTGCTGGCA
ATTGCGGTGGACCGCTACCTCCGGGTCAAGATCCCTCTCCGGTACAAGATGGTGGTGACC
CCCCGGAGGGCGGCGGTGGCCATAGCCGGCTGCTGGATCCTCTCCTTCGTGGTGGGACTG
ACCCCTATGTTTGGCTGGAACAATCTGAGTGCGGTGGAGCGGGCCTGGGCAGCCAACGGC
AGCATGGGGGAGCCCGTGATCAAGTGCGAGTTCGAGAAGGTCATCAGCATGGAGTACATG
GTCTACTTCAACTTCTTTGTGTGGGTGCTCCCCCCGCTTCTCCTCATGGTCCTCATCTAC
CTGGAGGTCTTCTACCTAATCCGCAAGCAGCTCAACAAGAAGGTGTCGGCCTCCTCCGGC
GACCCGCAGAAGTACTATGGGAAGGAGCTGAAGATCGCCAAGTCGCTGGCCCTCATCCTC
TTCCTCTTTGCCCTCAGCTGGCTGCCTTTGCACATCCTCAACTGCATCACCCTCTTCTGC
CCGTCCTGCCACAAGCCCAGCATCCTTACCTACATTGCCATCTTCCTCACGCACGGCAAC
TCGGCCATGAACCCCATTGTCTATGCCTTCCGCATCCAGAAGTTCCGCGTCACCTTCCTT
AAGATTTGGAATGACCATTTCCGCTGCCAGCCTGCACCTCCCATTGACGAGGATCTCCCA
GAAGAGAGGCCTGATGACTAG

# Drug_Target_4_General_Function:
Involved in A1 adenosine receptor activity, G-protein coupled

# Drug_Target_4_General_References:
1339301	Townsend-Nicholson A, Shine J: Molecular cloning and characterisation of a human brain A1 adenosine receptor cDNA. Brain Res Mol Brain Res. 1992 Dec;16(3-4):365-70.
1530647	Libert F, Van Sande J, Lefort A, Czernilofsky A, Dumont JE, Vassart G, Ensinger HA, Mendla KD: Cloning and functional characterization of a human A1 adenosine receptor. Biochem Biophys Res Commun. 1992 Sep 16;187(2):919-26.
8300646	Ren H, Stiles GL: Characterization of the human A1 adenosine receptor gene. Evidence for alternative splicing. J Biol Chem. 1994 Jan 28;269(4):3104-10.

# Drug_Target_4_HGNC_ID:
HGNC:262

# Drug_Target_4_HPRD_ID:
00042

# Drug_Target_4_ID:
16

# Drug_Target_4_Locus:
1q32.1

# Drug_Target_4_Molecular_Weight:
36512

# Drug_Target_4_Name:
Adenosine A1 receptor

# Drug_Target_4_Number_of_Residues:
326

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_4_Protein_Sequence:
>Adenosine A1 receptor
MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGA
LVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVT
PRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVISMEYM
VYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALIL
FLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFL
KIWNDHFRCQPAPPIDEDLPEERPDD

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase

# Drug_Target_4_SwissProt_ID:
P30542

# Drug_Target_4_SwissProt_Name:
AA1R_HUMAN

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
8.75

# Drug_Target_4_Transmembrane_Regions:
11-33
47-69
81-102
124-146
177-201
236-259
268-292

#END_DRUGCARD DB00640
